397 related articles for article (PubMed ID: 8837613)
1. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta.
Hughes DE; Dai A; Tiffee JC; Li HH; Mundy GR; Boyce BF
Nat Med; 1996 Oct; 2(10):1132-6. PubMed ID: 8837613
[TBL] [Abstract][Full Text] [Related]
2. Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
Narayana Murthy PS; Sengupta S; Sharma S; Singh MM
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):117-28. PubMed ID: 16797179
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and bone: new pieces to the puzzle.
Raisz LG
Nat Med; 1996 Oct; 2(10):1077-8. PubMed ID: 8837601
[No Abstract] [Full Text] [Related]
4. Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice.
Lee EJ; Kim JL; Kim YH; Kang MK; Gong JH; Kang YH
Phytomedicine; 2014 Sep; 21(10):1208-15. PubMed ID: 24932975
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
[TBL] [Abstract][Full Text] [Related]
6. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone.
Martin-Millan M; Almeida M; Ambrogini E; Han L; Zhao H; Weinstein RS; Jilka RL; O'Brien CA; Manolagas SC
Mol Endocrinol; 2010 Feb; 24(2):323-34. PubMed ID: 20053716
[TBL] [Abstract][Full Text] [Related]
7. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
Yang NN; Bryant HU; Hardikar S; Sato M; Galvin RJ; Glasebrook AL; Termine JD
Endocrinology; 1996 May; 137(5):2075-84. PubMed ID: 8612550
[TBL] [Abstract][Full Text] [Related]
8. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts.
Kameda T; Mano H; Yuasa T; Mori Y; Miyazawa K; Shiokawa M; Nakamaru Y; Hiroi E; Hiura K; Kameda A; Yang NN; Hakeda Y; Kumegawa M
J Exp Med; 1997 Aug; 186(4):489-95. PubMed ID: 9254647
[TBL] [Abstract][Full Text] [Related]
9. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
[TBL] [Abstract][Full Text] [Related]
10. Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: implications for estrogen deficiency-associated bone loss.
Finkelman RD; Bell NH; Strong DD; Demers LM; Baylink DJ
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):12190-3. PubMed ID: 1465458
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
12. In vivo effects of transforming growth factor-beta 2 in ovariectomized rats.
Kalu DN; Salerno E; Higami Y; Liu CC; Ferraro F; Salih MA; Arjmandi BH
Bone Miner; 1993 Sep; 22(3):209-20. PubMed ID: 8268754
[TBL] [Abstract][Full Text] [Related]
13. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
16. Short-term local injections of transforming growth factor-beta 1 decrease ovariectomy-stimulated osteoclastic resorption in vivo in rats.
Beaudreuil J; Mbalaviele G; Cohen-Solal M; Morieux C; De Vernejoul MC; Orcel P
J Bone Miner Res; 1995 Jun; 10(6):971-7. PubMed ID: 7572322
[TBL] [Abstract][Full Text] [Related]
17. Bone-protecting effect of Rubus coreanus by dual regulation of osteoblasts and osteoclasts.
Do SH; Lee JW; Jeong WI; Chung JY; Park SJ; Hong IH; Jeon SK; Lee IS; Jeong KS
Menopause; 2008; 15(4 Pt 1):676-83. PubMed ID: 18709701
[TBL] [Abstract][Full Text] [Related]
18. Osteoclasts and transforming growth factor-beta: estrogen-mediated isoform-specific regulation of production.
Robinson JA; Riggs BL; Spelsberg TC; Oursler MJ
Endocrinology; 1996 Feb; 137(2):615-21. PubMed ID: 8593810
[TBL] [Abstract][Full Text] [Related]
19. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss.
Kim TH; Jung JW; Ha BG; Hong JM; Park EK; Kim HJ; Kim SY
J Nutr Biochem; 2011 Jan; 22(1):8-15. PubMed ID: 20233653
[TBL] [Abstract][Full Text] [Related]
20. Increased Osteoblastic Cxcl9 Contributes to the Uncoupled Bone Formation and Resorption in Postmenopausal Osteoporosis.
Liu Z; Liang W; Kang D; Chen Q; Ouyang Z; Yan H; Huang B; Jin D; Chen Y; Li Q
Clin Interv Aging; 2020; 15():1201-1212. PubMed ID: 32764906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
